Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2001

View Archived Issues

Liposomal FGF-2 vaccine shows antiangiogenic efficacy

Venlafaxine compared to SSRIs in major depressive disorder

Abbott and NaPro BioTherapeutics file ANDA for paclitaxel

Prous Science announces publication of "Rational Approaches to Drug Design"

Adenosine A1 antagonist BG-9719 has beneficial effects in CHF

Hemodynamic, neurohumoral and other effects of long-term darusentan in CHF patients

Rosuvastatin shows good clinical results, as reported at ACC Scientific Session

Ranolazine proves beneficial in CHF patients with chronic angina; improves LV mechanical efficiency

Two new antiglaucoma drugs approved by FDA

Vernalis to clinically evaluate VML-670 for sexual dysfunction

New genomics-proteomics alliance announced by European firms

Neurogen and Pfizer advance GABA modulators for various indications

AAAAI news: steroidal antiinflammatory IPL-576092 has a profile distinct from glucocorticoids

Pharmacokinetics/pharmacodynamics of ezetimibe plus atorvastatin assessed

ICN's ribavirin granted orphan drug designation for treatment of hemorrhagic fever in E.U.

Preliminary clinical efficacy, safety and PK results for IDEC-152 presented at AAAAI meeting

Eplerenone improves endothelial function in rabbit model of atherosclerosis

Antisense oligonucleotides designed at Isis to modulate Akt-3

Novel antisense compounds as antiasthmatic, antiarthritic agents

Chemokine receptor antagonists and their use described by SB (now GSK)

Improved calanolide-related compounds identified in India as potential agents for HIV

Banyu discloses muscarinic M3 receptor antagonists particularly useful in asthma Rx

Heptapeptide LHRH antagonists in the Abbott pipeline

Aventis prepares new streptogramin B derivatives